| SCHEDULE OF BUSINESS SEGMENT |
SCHEDULE OF BUSINESS SEGMENT
| | |
March 31, 2025 | | |
December 31, 2024 | |
| | |
| | |
| |
| Healthcare | |
$ | 46,790,560 | | |
$ | 41,399,346 | |
| Labs and Life | |
| 16,503 | | |
| 26,646 | |
| Corporate and other | |
| 204,317 | | |
| 282,079 | |
| Total assets | |
$ | 47,011,380 | | |
$ | 41,708,071 | |
Summarized below is information about the Company’s
operations for the three months ended March 31, 2025 and 2024 by business segment:
| | |
Revenues | | |
Earnings/(Losses) | |
| | |
Three Months Ended March 31, 2025 | | |
Three Months Ended March 31, 2024 | | |
Three Months Ended March 31, 2025 | | |
Three Months Ended March 31, 2024 | |
| Healthcare | |
$ | 3,161,431 | | |
$ | - | | |
$ | (844,598 | ) | |
$ | - | |
| Labs and Life | |
| 8,489 | | |
| 7,180 | | |
| (23,005 | ) | |
| (159,450 | ) |
| | |
| | | |
| | | |
| (867,603 | ) | |
| (159,450 | ) |
| Corporate and other (a) | |
| - | | |
| - | | |
| 1,140,937 | | |
| (1,042,628 | ) |
| Interest expense | |
| - | | |
| - | | |
| (889,792 | ) | |
| (301,912 | ) |
| Total | |
$ | 3,169,920 | | |
$ | 7,180 | | |
$ | (616,458 | ) | |
$ | (1,503,990 | ) |
| (a) |
For the three months ended March 31, 2025, Corporate and other includes a $1.9 million gain from extinguishment of Senior PIK Notes, stock-based compensation, including amortization of consulting fees paid in stock, of $0.1 million and depreciation and amortization expense of $2,257. For the three months ended March 31, 2024, Corporate and other includes stock-based compensation, including amortization of consulting fees paid in stock, of $0.1 million and depreciation and amortization expense of $0.3 million. |
|